PDB54 COMPARISON OF TREATMENT COSTS BETWEEN BASAL-SUPPORTED ORAL THERAPY (BOT) WITH INSULIN GLARGINE (GLA) AND BOT WITH INSULIN DETEMIR (DET) IN PATIENTS WITH TYPE 2 DIABETES (T2D): ECONOMIC EVALUATION BASED ON THE RESULTS OF THE INSULIN GLARGINE (LANTUS®) VERSUS INSULIN DETEMIR (LEVEMIR®) TREAT-TO-TARGET (L2T3) STUDY
2010
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI